Previous studies reported that there was an association of high BCL2A1 expression with metastatic melanoma and hepatocellular carcinoma [25,26], which prompted us to consider the clinical function of BCL2A1 in ovarian cancer. Here, BCL2A1 is linked to hepatocellular carcinoma.